NAD+ and Sirtuin Research: Deacylase Pathways, Aging Biology, and Metabolic Regulation

Sirtuins (SIRT1-7) are a family of NAD+-dependent protein-modifying enzymes that regulate aging-related processes including mitochondrial biogenesis, DNA repair, stress response, metabolic adaptation, and telomere maintenance. They cannot function without NAD+ as a cosubstrate. NAD+ decline with aging impairs all seven sirtuins, which may coordinate multiple aging hallmarks simultaneously. Published NAD+ supplementation research in animal models restores sirtuin activity; human data is preliminary. See NAD+ overview, NAD+ longevity trial review, NAD+ product page.

Sirtuin: A family of seven (SIRT1-7) evolutionarily conserved NAD+-dependent protein deacylases. Named after Sir2 (Silent Information Regulator 2) in yeast, the founding member discovered to extend yeast lifespan. Sirtuins remove acyl groups (acetyl, succinyl, malonyl, etc.) from lysine residues on target proteins, regulating their activity.

Deacylase: An enzyme that removes acyl groups (acetyl, propionyl, succinyl, malonyl, crotonyl) from lysine residues of proteins. Acylation of lysine blocks the positive charge and alters protein-protein interactions, DNA binding, and enzyme activity. Deacylation restores the positive charge and reverses these effects.

NAD+ (nicotinamide adenine dinucleotide): The oxidized form of the essential coenzyme. In sirtuin catalysis, NAD+ is cleaved into nicotinamide and the ADP-ribose-acyl product (O-acyl-ADP-ribose); NAD+ is consumed in every reaction cycle.

SIRT1: The most studied sirtuin; nuclear and cytoplasmic. Deacetylates PGC-1alpha, FOXO3, p53, NF-kB, and dozens of additional targets. A master metabolic and stress-response regulator.

SIRT3: The major mitochondrial sirtuin. Deacetylates and activates Complex I and III subunits of the ETC, IDH2 (TCA cycle), SOD2 (antioxidant defense), and many mitochondrial metabolic enzymes.

SIRT6: A nuclear sirtuin with roles in DNA double-strand break repair (via deacetylation of histone H3K9 at DSB sites) and telomere maintenance (deacetylates H3K9 at telomeres, enabling TRF1 binding and protecting telomere structure).

PGC-1alpha: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha. The master regulator of mitochondrial biogenesis. SIRT1 deacetylates PGC-1alpha, activating it to drive new mitochondria formation.

FOXO3: A forkhead transcription factor that activates genes for stress resistance, autophagy, and longevity. SIRT1 deacetylates and activates FOXO3, directing it to express antioxidant and DNA repair genes rather than apoptosis genes.

Sirtuins were discovered in the context of aging research. Sir2 (Silent Information Regulator 2) in yeast was found to extend lifespan when overexpressed and shorten lifespan when deleted. The human homolog SIRT1 was subsequently characterized by Imai, Guarente, Sinclair, and colleagues in landmark papers published in Nature and Cell from 2000 onwards.

The key biochemical discovery (Imai et al., Nature 2000, PMID 10963409) was that Sir2 is not a conventional enzyme but a unique NAD+-dependent deacetylase: it requires NAD+ as a cosubstrate and is completely inactive without it. This was biochemically unexpected and immediately suggested that Sir2/SIRT1 activity would be directly tied to cellular NAD+ levels.

The discovery created the following logical chain: if NAD+ is required for sirtuin function, and NAD+ declines with aging, then sirtuin activity must decline with aging. And if sirtuin activity is required for longevity pathways (as the yeast lifespan data suggested), then age-related NAD+ decline could be a mechanism by which aging disrupts longevity-promoting gene regulation.

This hypothesis has driven two decades of NAD+ and sirtuin research and remains the primary scientific rationale for NAD+ supplementation approaches in aging biology.

SIRT1 is the best characterized sirtuin with the broadest published substrate list. Key targets and their significance:

PGC-1alpha deacetylation: SIRT1 deacetylates (and thereby activates) PGC-1alpha, the master regulator of mitochondrial biogenesis. When NAD+ is adequate (indicating metabolic need), SIRT1 is active, PGC-1alpha is deacetylated, and mitochondrial biogenesis is stimulated. When NAD+ declines (energy excess or aging), SIRT1 activity falls, PGC-1alpha remains acetylated and inactive, mitochondrial biogenesis is impaired, and the number and quality of mitochondria declines.

FOXO3 deacetylation: SIRT1 deacetylates FOXO3, shifting its transcriptional program from apoptosis to stress resistance and autophagy. FOXO3 deacetylation induces antioxidant genes (SOD2, catalase) and autophagy genes (LC3, Beclin-1), enhancing the cell's capacity to manage oxidative stress and clear damaged proteins.

p53 deacetylation: SIRT1 deacetylates p53, suppressing its pro-apoptotic transcriptional activity. This shifts the p53 response from apoptosis toward cell cycle arrest and DNA repair, potentially relevant to genomic stability under mild stress.

NF-kB deacetylation: SIRT1 deacetylates the RelA/p65 subunit of NF-kB, reducing transcription of pro-inflammatory cytokines. This anti-inflammatory function connects SIRT1 to the chronic low-grade inflammation of aging (inflammaging).

For the mitochondrial context: mitochondria and aging research, MOTS-c exercise research.

SIRT3 is the primary mitochondrial sirtuin and the most critical for mitochondrial metabolic function in the context of NAD+ biology.

ETC complex activation: SIRT3 deacetylates multiple subunits of Complex I, II, and III of the mitochondrial electron transport chain (ETC). Acetylation inhibits ETC activity; SIRT3-mediated deacetylation restores optimal ETC function. When SIRT3 is inhibited by NAD+ decline, ETC complexes become hyperacetylated and less efficient, producing more electron leak (and thus more superoxide) per unit of ATP generated.

SOD2 activation: SIRT3 deacetylates and activates manganese superoxide dismutase (SOD2/MnSOD), the primary mitochondrial antioxidant enzyme. SOD2 converts superoxide (O2-) to hydrogen peroxide, which is then cleared by catalase and glutathione peroxidase. Inhibited SOD2 allows superoxide accumulation, oxidative protein damage, and mitochondrial dysfunction.

IDH2 activation: Isocitrate dehydrogenase 2 (IDH2) is a TCA cycle enzyme that also regenerates NADPH (a reducing equivalent needed for antioxidant defense) in mitochondria. SIRT3 activates IDH2 by deacetylation, supporting both TCA cycle flux and mitochondrial antioxidant capacity.

SIRT3 and aging: SIRT3 expression and activity decline significantly with age. SIRT3 knockout mice show accelerated mitochondrial dysfunction, elevated oxidative stress, and metabolic disease. SIRT3 overexpression protects against age-related mitochondrial decline in published animal studies.

For SS-31's complementary mitochondrial mechanism: SS-31 elamipretide clinical evidence, SS-31 heart failure research.

SIRT6 is a nuclear sirtuin with two distinct published roles in genomic stability: DNA double-strand break (DSB) repair and telomere maintenance.

DNA DSB repair: When DNA double-strand breaks occur, SIRT6 is rapidly recruited to the break site. SIRT6 deacetylates histone H3K9 and H3K56 at the break site, relaxing chromatin and enabling DNA repair machinery to access the lesion. SIRT6-deficient cells show impaired DSB repair and genomic instability.

Telomere maintenance: Telomeres require SIRT6-mediated H3K9 deacetylation for proper TRF1 (telomeric repeat-binding factor 1) association. Without SIRT6 activity, H3K9 becomes hyperacetylated at telomeres, TRF1 cannot bind properly, and telomeres fail to fully replicate, leading to telomere shortening and chromosomal instability.

SIRT6 knockout aging phenotype: SIRT6 knockout mice develop a dramatic premature aging syndrome with features including kyphosis, lymphopenia, loss of subcutaneous fat, organ degeneration, and early death (median lifespan approximately 4 weeks). This represents one of the most severe premature aging phenotypes of any single gene knockout, strongly implicating SIRT6 in normal aging biology.

SIRT6 overexpression: Male mice with SIRT6 overexpression show extended lifespan versus controls in published studies (Kanfi et al., Nature 2012), providing evidence that SIRT6 is not merely required for normal aging but may be rate-limiting for lifespan.

The mechanistic case for age-related NAD+ decline as a driver of sirtuin dysfunction rests on several converging published findings:

Magnitude of NAD+ decline: Published measurements in human and animal tissue show NAD+ levels decline 40-60% between young adulthood and old age in multiple tissues including liver, kidney, heart, and brain. This is not a trivial reduction; it represents a substantial impairment of NAD+-dependent enzyme function.

Mechanisms of decline: Three primary mechanisms drive age-related NAD+ decline: (1) increased PARP activity due to age-related DNA damage accumulation; (2) increased CD38 (a NAD+-consuming enzyme) expression in aging tissue, particularly in senescent cells and macrophages; (3) reduced NAMPT (nicotinamide phosphoribosyltransferase) activity, limiting the rate of NAD+ biosynthesis from its salvage precursors.

Consequence for sirtuins: Published biochemical data shows that SIRT1, SIRT3, and SIRT6 activity are directly proportional to intracellular NAD+ at the concentrations seen in aging tissue. A 50% reduction in NAD+ produces a proportionate reduction in sirtuin catalytic activity. This means the age-related NAD+ decline predictably impairs all seven sirtuins simultaneously.

Sirtuin activity restoration by NAD+ repletion: Published animal studies show that restoring NAD+ levels (through NMN or NR precursor supplementation) in aged animals restores SIRT1, SIRT3, and SIRT6 activity markers to young-animal levels. This provides proof-of-concept that the NAD+-sirtuin axis is pharmacologically targetable.

NAD+ precursor supplementation research has produced a substantial body of published preclinical and emerging human data:

Animal preclinical data (strong): Multiple published studies in mice show NMN and NR supplementation restores NAD+ levels, activates sirtuin pathways (measured by target protein deacetylation), improves mitochondrial function (SIRT3 targets), restores muscle function, improves metabolic parameters, and in some studies extends healthspan. This preclinical data is robust and reproducible across multiple laboratories.

Human pharmacokinetic data (established): Published human clinical trials confirm that oral NMN and NR increase circulating NAD+ metabolites. Multiple Phase 1/2 studies have demonstrated safety and NAD+ elevation in human participants.

Human sirtuin pathway activation (limited): Whether human NAD+ supplementation sufficiently restores intracellular NAD+ to physiologically meaningful levels in the tissues where aging matters (heart, brain, skeletal muscle) is less established. Blood NAD+ elevation does not necessarily reflect intracellular tissue levels. Some published human data shows improvement in sirtuin pathway biomarkers (e.g., SIRT1-dependent gene expression) after supplementation, but this is not uniformly consistent.

Human clinical outcomes (incomplete): Large outcome trials examining whether NAD+ supplementation reduces age-related disease, improves functional outcomes, or extends healthy lifespan have not been published as of 2026. The mechanistic case is strong; clinical translation requires further evidence.

Calibrating the evidence is essential for NAD+ sirtuin research:

Model organism evidence: Strong lifespan extension through sirtuin manipulation in yeast, nematodes, and fruit flies. Less consistent in mice; the magnitude of lifespan extension in mice is smaller and more variable across studies.

Human sirtuin biology: Sirtuins are conserved from yeast to humans, but the precise roles may differ. Human SIRT1 has additional regulatory mechanisms not present in simpler organisms. The calorie restriction-sirtuin-longevity link that is robust in lower organisms is less clearly established in primates.

Measurement challenges: Measuring sirtuin activity in specific tissues in living humans is technically difficult. Most human NAD+ supplementation studies measure blood biomarkers rather than tissue sirtuin activity directly.

Supplement heterogeneity: NAD+ precursors (NMN, NR, nicotinic acid, NAD+ itself) have different bioavailability and tissue distribution profiles. Results from one precursor may not generalize to others.

For comprehensive NAD+ context: NAD+ overview, NAD+ longevity trial review, NAD+ addiction research. For mitochondrial connections: MOTS-c deep dive, SS-31 product page, mitochondria and aging research.

For the full NAD+ research picture: NAD+ overview, NAD+ longevity trial review, NAD+ addiction research, NAD+ product page. For mitochondrial energy and longevity: MOTS-c deep dive, MOTS-c exercise research, SS-31 elamipretide clinical evidence, mitochondria and aging research. For storage and quality: how to read a COA, storage and handling guide.